The TMPRSS2:ERG gene fusion is specific for prostate cancer, and the ability to identify this DNA rearrangement could be used as a screening test for prostate cancer in serum, prostatic fluid, or in urine. Here, TMPRSS2 is linked to prostate carcinoma.